MEMBER LOGIN: Your Email: Password: Remember Me
Forgot Your Password or would like to register?
MDT Medtronic
As Of 4/25/2018 7:17:00 PM
Current Price$79.46
Current Rating2
Return Since 5/2015
Medtronic13.16 %
S&P 50026.47 %
VFS Rating Analysis
Related Links
Company News
Earnings Call Transcripts
Options Chain
Options Pricing History
For current estimates, historical performance information and more, Log in to your account.

Monthly Performance and Prediction History
Below is the monthly performance history for this security and the monthly change as compared to the stock market for this security. When a row is highlighted in green, it is identifying a stock that the model predict will outperform the portfolio for that month. When a row is highlighted in red, it is identifying a stock that the model predicted will underperform for the month. No highlight indicates the model is neutral on the stock. These predictions are always recorded at the beginning of the month, and table below shows the resulting return for the month.
DateVFS RatingPredictionRating PriceSubsequent
% Increase
Market %
Increase *
4-01-20182 $80.22   
* As measured by the performance of the S&P 500 for the month.

MDT25Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions ( 7:02:00 AM
MDT25Medtech Supplier IntriCon Rallies After Bullish Stifel Initiation ( 10:40:00 AM
MDT25Medtronic Expands Focus on Interventional Oncology with Its U.S. Launch of OptiSphere(TM) Embolization Spheres ( 8:02:00 AM
MDT20ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement ( 5:30:00 AM
MDT20Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves ( 2:02:00 PM
MDT20Medtronic's Portfolio Is Unmatched ( 4:00:00 AM
MDT15Sanofi’s 1Q18: Revenue Expected to Fall ( 10:00:00 AM
MDT15Will BSX’s 1Q18 Results Support Its Upward Trend? ( 6:02:00 AM
MDT15Boston Scientific: The Word on Wall Street ahead of 1Q18 Earnings ( 12:58:00 PM
MDT15Tandem Diabetes Care Inc Is Up 194% — And It’s Not Done Yet ( 8:36:00 AM
MDT15Abbott’s Latest Valuation Metrics in April 2018 ( 4:31:00 AM
JNJ, MDT12Johnson & Johnson’s Revenues Continued to Rise in 1Q18 ( 1:49:00 PM

WEBSITE DISCLAIMER:  Puget Investors and Vertical Financial Systems, Inc are not registered investment advisers, broker/dealers, or research analysts/organizations. The content on this website is issued solely for information purposes and should not to be construed as an offer to buy, sell, or trade in any way, any security mentioned herein.

All information presented on this website is believed to be reliable and written in good faith, but no representation or warranty, expressed or implied is made as to their accuracy, completeness or correctness. You are responsible for doing your own research before investing in any securities mentioned herein. Readers are urged to consult with their own independent financial advisors with respect to any investment. Neither Vertical Financial Systems, Inc, nor its officers or employees accept any liability whatsoever for any direct or consequential loss arising from any use of information on this website.

Past performance is not a guarantee of future performance or accuracy. Rating calculations and methodology may change at any time, and we reserve the right to make changes which may impact the accuracy of the model without prior notice to anybody.

Be advised that employees and officers of Vertical Financial Systems, Inc and may hold positions in the securities mentioned in this website.
Website Operated by Vertical Financial Systems, Inc